real estate in the boston biopharma ecosystem
Post on 24-Dec-2021
3 Views
Preview:
TRANSCRIPT
1
REAL ESTATE IN THE BOSTON BIOPHARMA ECOSYSTEM
What Leaders Need to Know to Navigate the Market
2 3
ABOUT THIS REPORTBoston has emerged as one of the most dynamic, rapidly growing BioPharma ecosystems in
the United States with more than 550 active companies and 74,000 people employed in the
life sciences industry.1
The Massachusetts Biotechnology Education (MassBioEd) Foundation’s 2018 Annual Job
Trends Forecast projects that Massachusetts will need to fill nearly 12,000 additional jobs by
May of 2023 to meet rising demand.2 And the industry is forecast to remain hotter than ever.
So, what does this mean for the Boston BioPharma ecosystem? How can companies establish
themselves and grow in this fast-paced network?
In this report, we’ll uncover how Boston’s real estate market has responded to rapid
BioPharma growth and how BioPharma leaders can plan for and execute effective real estate
strategies to enable growth in a highly competitive marketplace.
1 http://www.liftstream.com/boston-biotech-cluster.html2 https://www.massbioed.org/writable/files/JobTrends/massbioed_jobs_trend_report_2018_final_web.pdf
4 5
THE VIEW FROM 30,000 FEET
Boasting leading institutions, including Harvard, MIT, University of Massachusetts, and Boston University, along with five of the eight top-NIH funded hospitals in the US, and more than 550 active companies in the life sciences industry3, it’s no wonder Boston has become one of the top BioPharma hubs in the United States.
In fact, the Massachusetts Biotechnology Education (MassBioEd) Foundation reveals that employment in the life sciences sector surpassed 70,000 people for the first time in history in 2017.4 They project that Massachusetts will need to fill nearly 12,000 additional jobs by May of 2023 to meet rising demand, and they see no sign of the life sciences industry slowing.5
3 http://www.liftstream.com/boston-biotech-cluster.html4 https://www.massbioed.org/writable/files/JobTrends/massbioed_jobs_trend_report_2018_final_web.pdf5 https://www.massbioed.org/writable/files/JobTrends/massbioed_jobs_trend_report_2018_final_web.pdf
6 7
Massachusetts has also emerged as a global hub for biotech investments, with venture
capital (VC) dollars continuing to flood into the state’s BioPharma companies, reaching $2.9
billion in 2016—up from $2.3 billion in 2015 and more than three times the $900 million
invested in 2012.6 Many of the leading VC firms are either headquartered or have offices in
Boston or Cambridge. And an astounding 30% of all US-based biotech IPOs in 2016 were from
Massachusetts-based companies.7
Most of this growth is being fueled by companies and investors gathering together in a
geographic BioPharma cluster centered in Cambridge. In 2017, Genetic Engineering &
Biotechnology News (GEN) placed Boston/Cambridge at the top of its annual top 10 ranking
of BioPharma clusters based on job availability, patents issued, available lab space, and NIH
and VC funding.8 It’s one of two key geographic clusters dominating the biotech industry
today—the other being the San Francisco Bay area. Bruce Booth, D.Phil., a partner at Atlas
Venture, attributes this to those areas’ unique blend of biomedical science, venture capital,
entrepreneurial talent, risk-taking culture, and geographic density.9
6 https://www.massbio.org/news/recent-news/massbio-s-2017-industry-snapshot-shows-venture-capital-investment-in- massachusetts-biopharma-industry-reached-a-record-2-9-billion-lastyear-1375927 https://www.massbio.org/news/recent-news/massbio-s-2017-industry-snapshot-shows-venture-capital-investment-in- massachusetts-biopharma-industry-reached-a-record-2-9-billion-lastyear-1375928 https://www.genengnews.com/the-lists/top-10-us-biopharma-clusters/779009179 https://lifescivc.com/2017/03/inescapable-gravity-biotechs-key-clusters-great-consolidation-talent-capital-returns/
The BioPharma boom
in such a concentrated
geographic area has led to
an extremely competitive
marketplace. Today,
companies must plan well
and work hard to woo
top talent to their teams,
stand out from the pack
to attract VC funding,
and secure effective real
estate in a tight market
as they move through
their often-unpredictable
growth trajectories.
8 9
BOSTON REAL ESTATE: WHERE BIOPHARMA WORKS
Boston’s Vibrant BioPharma Hubs
The BioPharma real estate ecosystem in Boston is well established, growing rapidly, and
highly competitive. BioPharma companies have congregated in several areas, creating highly
concentrated hubs where small startups, growth-mode companies, and some of the largest
BioPharma companies in the world compete with other large firms, like Google, Amazon, and
Microsoft, for real estate in a very tight market.
Cambridge—more specifically Kendall Square—is ground zero, with Biogen landing there
in the early 1980s and Genzyme taking up residency a few years later. Other startups eager
to make their mark in the BioPharma market have followed, as have larger firms looking to
capitalize on Boston’s talent.
10 11
Area expert Jeremy Hood, Senior Principal at T3 Advisors, asserts Cambridge became
the original BioPharma hub because of its access to talent and proximity to a wealth of
universities, like MIT and Harvard.
Recent research by Deloitte has also highlighted a major shift in the industry towards
more collaborative partnerships among life sciences companies, academia, nonprofits,
and government entities. About 9,000 new BioPharma research and development (R&D)
partnerships were formed between 2005 and 2014—more than double the number formed
in the preceding decade.10 Being near one another helps these cross-party stakeholders
collaborate more fluidly.
Today, Cambridge remains Boston’s premier BioPharma hub, but other areas show promise
of becoming vibrant centers in their own right. Real estate investors are developing
properties in Boston neighborhoods, like the Seaport and Fenway, as well as suburban areas,
including Waltham and Lexington. And with increased funding driving rapid growth, the
Boston BioPharma real estate market is expected to continue to swell.
10 https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/how-biopharma-collaborations-are-fueling- biomedical-innovation.html
Low Vacancy, High Cost, Stiff Competition
As the top BioPharma hub in the Boston area, Cambridge is experiencing high demand for
commercial real estate, driving low vacancy rates and escalating rents. The vacancy rate in
the overall Cambridge market hovers around 1%, with average costs per square foot running
$52 in West Cambridge, $74 in Mid-Cambridge, and $86 in East Cambridge—which is
currently the hottest BioPharma real estate submarket in greater Boston.
Newer hubs are providing other options, but supply across the entire area struggles to keep
up with the growing demand. One contributing factor is the limited number of landlords
focused on BioPharma real estate; only three to five market-wide are proactively searching
out life sciences tenants and building lab space.
According to Hood, “BioPharma real estate is extremely specialized. Lab space must be built
to certain specifications for concerns like venting of chemical vapors, properly disposing of
hazardous waste, and providing necessary equipment with sufficient electricity. This requires
a considerably more robust, expensive infrastructure than the typical office building.”
12 13
“Because the market has gotten so tight, some companies have made more reactionary decisions: taking space that may not suit their needs, that hasn’t been properly vetted, or that can’t be built out to accommodate their science—all just because it’s available space.”
—Jeremy Hood Senior Principal T3 Advisors
Another complicating factor is the recent “pre-leasing” phenomenon. New projects are
under way, but due to high demand, big pharma and tech companies are pre-leasing the
space before it even hits the market, making it difficult for scaling life sciences companies to
find the right property when they need it.
“It’s challenging to find initial space, but the real difficulty comes when companies need to
grow beyond it,” advised Hood. “So, we find firms taking multiple spaces around Kendall
Square or leasing earlier in the life cycle than needed, often subleasing to other companies for
shorter terms to reserve real estate for themselves later. People are jumping on any available
open space. That can be a dangerous move.”
14 15
Planning for Uncertain Outcomes
In addition to dealing with a competitive real estate market, BioPharma companies face
a unique challenge. The pace at which a company grows is dependent on the outcomes of
unpredictable activities, including scientific experiments, fundraising, clinical trials, and
government approvals. Positive results aren’t guaranteed.
So, while it’s relatively straightforward for a small startup to find effective lab space for
R&D, it’s much more difficult to plan for growth—preparing to hire more people and expand
office space to support Clinical, Finance, Sales, and Marketing Teams. Companies want to be
prepared, but they don’t know how much space they will need or when they will be ready to
expand. It depends on the outcomes of many activities along an uncertain path through the
life cycle.
16 17
HOW BIOPHARMA LEADERS CAN NAVIGATE THIS CHALLENGING MARKET
BioPharma leaders have a lot to consider when evaluating real estate in the Boston area. The
goal is to secure effective space that enables employees to do their best work and supports
the company as it moves through its growth trajectory. Given the industry’s unpredictable
nature and the area’s competitive real estate market, sound, up-front analysis and planning
is crucial to preventing potentially costly mistakes.
1. Plan early for multiple growth scenarios.During early planning stages, leaders should consider multiple
forward-looking scenarios as they create their real estate strategy.
How many and what types of people will the company need if they
meet their growth goals? What if they grow more slowly or quickly
than planned? How does each situation impact the size and timing
of real estate requirements?
Understanding multiple scenarios enables sound real estate
planning. The earlier they’re defined, the more likely a company is
to have access to workable space when needed.
How can BioPharma leaders plan their real estate journey as they scale? Here are six pieces of advice to consider.
18 19
2. Understand the science needs and goals.Space is more than just an expense or a cool place to attract talent.
It can be a tool to empower employees, enable the science, and
propel a company forward.
That can only happen, however, with a foundational understanding
of the science needs and goals. Is the company doing chemistry-
based R&D that requires specific ventilation? Is there a need for
refrigeration for biotech? Will there be animal testing that requires
special facilities?
Having answers to questions like these and understanding the
impact they have on real estate requirements is essential to finding
space that will not only work, but can dramatically accelerate
growth.
3. Know who the company is hiring and when.Attracting and retaining top talent is competitive in the current
market, but it’s critical for success, and people care about the
space in which they work. Companies need to understand who
they will need at each stage of growth. What are their roles? How
many of each? Where will candidates likely live? Will they be PhDs
fresh from MIT or Harvard who live close to Cambridge or more
experienced people who live farther out?
Understanding the people behind the science informs many
decisions and is particularly important when deciding which areas
have the potential to attract top talent and minimize the burden of
long commutes.
20 21
4. Take a data-driven approach to location analysis.Executives often think they have to be in a specific neighborhood.
In this tight market, however, it makes sense to consider multiple
options, evaluating the costs and locations of key stakeholders—
not just employees, but also investors, key vendors, and strategic
partners. Where do employees and future hires live? How often will
they be in the lab or office? Who will they be working with most often?
A commute analysis tool can provide additional value with real data
to support decision making. Companies can also survey employees
to find out how they prefer to commute. Hood has seen companies
assume they need to locate near a Red Line stop, only to find out
through surveys that this wasn’t important to most employees,
who either didn’t live near the Red Line, carpooled with others, or
preferred to Uber to work.
Taking a data-driven approach provides the transparency needed to
make objective decisions that will improve productivity and quality
of life.
5. Optimize space for how people work.Getting the most out of any workspace is important, but especially
so in research labs. Labs are not only expensive, but their layout
can also impact the quality and speed of R&D. So, it’s important to
clearly define and optimize each functional area, configuring each
lab based on the specific work processes that will be performed, so
individuals have easy access to the supplies and equipment they
need and enough space to do their jobs efficiently.
Additionally, keep in mind that science rarely goes from “Point A”
to “Point B,” so lab design should be flexible and reconfigurable
to accommodate process changes. Continuously analyze ways to
make the space more efficient. According to Hood, “Your facility
needs to enable your science. Do it right, and your science will be
better supported.”
22 23
6. Engage with a strong real estate partner.Real estate is a significant investment for BioPharma companies, primarily
due to the specific requirements for lab space. An experienced advisor
with a BioPharma focus and extensive knowledge of the Boston real estate
market can help companies invest wisely.
A high-quality advisor will gather a lot of information to guide the
search, but analysis and decision making should always be driven by a
deep understanding of the science, the people responsible for advancing
it, and how space can enable their work. An advisor should represent
the business as the future tenant and oversee the process from start to
finish—determining the company’s needs, evaluating locations and
sites, negotiating leases, and working with tenants to manage design and
construction planning and execution.
An advisor should also be invested in long-term outcomes—helping the
company plan as soundly as possible for each phase of growth—ensuring that
the space propels the science and drives the company to a successful exit.
LEARN MORESince 2001, we’ve helped the world’s most innovative life science companies use space as a
platform to advance their science. We can create a custom real estate strategy that meets your
company’s growth and cultural goals.
Have a true advocate
We only represent tenants, which means we have no conflicts of interest. This ensures you get access to the best spaces and get the best deal terms.
Problem solve at every stage
From understanding clinical milestones, to fundraising and M&A, our exclusive focus on life science companies and investors helps us anticipate challenges and provides you with proactive solutions.
Do more with your space
Mechanical, electrical, and plumbing systems are critical to support labs and experiments. We help you scale your facility with your science and headcount growth to ensure it can grow with you.
Minimize upfront costs
Because lab space can be so costly to build out, we perform due diligence on every potential facility to ensure there are no surprises, negotiating to minimize your risk and expenses.
24
LEARN MORE AT T3ADVISORS.COM
SAMPLE CLIENTS
T3ADVISORS.COMBOSTON | NEW YORK | SAN FRANCISCO | PALO ALTO
MakersEntrepreneursCreatorsThinkersNegotiators
top related